BSS is a Ophthalmic Solution in the Human Prescription Drug category. It is labeled and distributed by Alcon Laboratories, Inc.. The primary component is Calcium Chloride; Magnesium Chloride; Potassium Chloride; Sodium Acetate; Sodium Chloride; Sodium Citrate.
| Product ID | 0065-0795_19d9e9e4-f86c-4139-8c67-e5f88c828ecf |
| NDC | 0065-0795 |
| Product Type | Human Prescription Drug |
| Proprietary Name | BSS |
| Generic Name | Balanced Salt Solution |
| Dosage Form | Solution |
| Route of Administration | OPHTHALMIC |
| Marketing Start Date | 1969-03-28 |
| Marketing Category | NDA / NDA |
| Application Number | NDA020742 |
| Labeler Name | Alcon Laboratories, Inc. |
| Substance Name | CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE |
| Active Ingredient Strength | 0 mg/mL; mg/mL; mg/mL; mg/mL; mg/mL; mg/mL |
| Pharm Classes | Blood Coagulation Factor [EPC], Calcium [CS], Calculi Dissolution Agent [EPC], Cations, Divalent [CS], Increased Coagulation Factor Activity [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 1969-03-28 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA020742 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1969-03-28 |
| Marketing Category | NDA |
| Application Number | NDA020742 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1969-03-28 |
| Marketing End Date | 2016-04-06 |
| Marketing Category | NDA |
| Application Number | NDA020742 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1969-03-28 |
| Marketing Category | NDA |
| Application Number | NDA020742 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1969-03-28 |
| Marketing End Date | 2018-12-31 |
| Ingredient | Strength |
|---|---|
| SODIUM CHLORIDE | 6.4 mg/mL |
| SPL SET ID: | 4bd4d59c-eb3b-4a5e-9eb7-ae95b0a92bea |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0065-0795 | BSS | balanced salt solution |
| 0065-1795 | BSS | balanced salt solution |